The article discusses the complex role of the tumor microenvironment (TME) in cancer progression and metastasis. Tumors rely on the TME for growth, invasion, and metastasis, with stromal cells playing a critical role. Unlike tumor cells, stromal cells are genetically stable, making them attractive therapeutic targets. However, disrupting the TME is challenging due to its dual role in promoting and inhibiting tumorigenesis. Recent studies suggest that reeducating stromal cells, rather than ablating them, may be more effective in treating cancer. The TME is crucial for both normal tissue homeostasis and tumor growth. Tumor cells interact with the stroma, influencing disease initiation, progression, and prognosis. Chronic inflammation is linked to tumorigenesis, as observed by Rudolf Virchow in 1863. The TME is now understood to be diverse, influenced by stromal cell composition and activation states. As tumors grow, the TME continuously changes, highlighting the need to consider TME influences on metastasis as a dynamic process. The article reviews current research on the role of different stromal compartments in cancer development and metastasis, and recent therapeutic strategies targeting the tumor-associated stroma. It discusses the clinical associations between immune modulation and tumor incidence, highlighting the paradoxical nature of immune responses in cancer. Tumor-associated macrophages (TAMs) play a significant role in tumor growth, with their polarization state influencing their pro-tumorigenic or anti-tumorigenic effects. Reversing TAMs to an M1 phenotype can lead to tumor regression. Myeloid-derived suppressor cells (MDSCs) and regulatory T (Treg) cells also contribute to immune suppression in cancer. MDSCs promote tumor progression by suppressing immune responses, while Treg cells can have diverse effects on tumorigenesis. Cancer-associated fibroblasts (CAFs) elicit pro-tumorigenic functions by supporting tumor growth and metastasis. The tumor vasculature is supported by the TME, with angiogenesis being a key factor in tumor growth. The article also discusses the role of the extracellular matrix (ECM) in tumor progression, highlighting its capacity to limit cancer initiation and drive disease progression. The tumor vasculature is supported by the TME, with angiogenesis being a key factor in tumor growth. The TME supports cancer cell dissemination and survival in the periphery, with stromal influences on phenotypic switching playing a critical role in metastatic outgrowth. The article reviews the mechanisms of cellular dormancy, including cell cycle arrest and immune-induced tumor dormancy. Immune surveillance can lead to tumor dormancy, with immune-edited tumors at risk of exiting equilibrium. Tumor awakening and metastatic outgrowth are influenced by immune evasion and the ability to establish a global immunosuppressive state in the TME. The article concludesThe article discusses the complex role of the tumor microenvironment (TME) in cancer progression and metastasis. Tumors rely on the TME for growth, invasion, and metastasis, with stromal cells playing a critical role. Unlike tumor cells, stromal cells are genetically stable, making them attractive therapeutic targets. However, disrupting the TME is challenging due to its dual role in promoting and inhibiting tumorigenesis. Recent studies suggest that reeducating stromal cells, rather than ablating them, may be more effective in treating cancer. The TME is crucial for both normal tissue homeostasis and tumor growth. Tumor cells interact with the stroma, influencing disease initiation, progression, and prognosis. Chronic inflammation is linked to tumorigenesis, as observed by Rudolf Virchow in 1863. The TME is now understood to be diverse, influenced by stromal cell composition and activation states. As tumors grow, the TME continuously changes, highlighting the need to consider TME influences on metastasis as a dynamic process. The article reviews current research on the role of different stromal compartments in cancer development and metastasis, and recent therapeutic strategies targeting the tumor-associated stroma. It discusses the clinical associations between immune modulation and tumor incidence, highlighting the paradoxical nature of immune responses in cancer. Tumor-associated macrophages (TAMs) play a significant role in tumor growth, with their polarization state influencing their pro-tumorigenic or anti-tumorigenic effects. Reversing TAMs to an M1 phenotype can lead to tumor regression. Myeloid-derived suppressor cells (MDSCs) and regulatory T (Treg) cells also contribute to immune suppression in cancer. MDSCs promote tumor progression by suppressing immune responses, while Treg cells can have diverse effects on tumorigenesis. Cancer-associated fibroblasts (CAFs) elicit pro-tumorigenic functions by supporting tumor growth and metastasis. The tumor vasculature is supported by the TME, with angiogenesis being a key factor in tumor growth. The article also discusses the role of the extracellular matrix (ECM) in tumor progression, highlighting its capacity to limit cancer initiation and drive disease progression. The tumor vasculature is supported by the TME, with angiogenesis being a key factor in tumor growth. The TME supports cancer cell dissemination and survival in the periphery, with stromal influences on phenotypic switching playing a critical role in metastatic outgrowth. The article reviews the mechanisms of cellular dormancy, including cell cycle arrest and immune-induced tumor dormancy. Immune surveillance can lead to tumor dormancy, with immune-edited tumors at risk of exiting equilibrium. Tumor awakening and metastatic outgrowth are influenced by immune evasion and the ability to establish a global immunosuppressive state in the TME. The article concludes